IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

LEVIN et al

09/618,759 Serial No.

July 18, 2000 Filed:

Washington, DC 20231

Atty. Ref.: 3659-10

Group: 3762

Examiner:

For: METHOD AND APPARATUS FOR PERIPHERAL VEIN FLUID

REMOVAL IN HEART FAILURE

Assistant Commissioner for Patents

December 22, 2000

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

\boxtimes	1.	PTO-1449 Pursuant to 37 CFR 1.97(b)	
		[within 3 months of filing or prior to 1st Office Action]	N/C
	2.	Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance]	N/C
	3.	Fee Payment Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance]	\$180.00
	4.	Petition, Statement & Petition Fee Payment Pursuant ([before Issue Fee payment]	to 37 CFR 1.97(d) \$130.00

Assistant Commissioner for Patents Washington, DC 20231

Sir:

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

 \boxtimes A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document is enclosed herewith.

This paper is submitted in accordance with:

冈 6. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]

Ш	1.	CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and				
		The required Statement made in item 9 below; or				
		The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 10 below.				
	8.	37 CFR §1.97(d): [before issue fee payment]; and				
		This is a petition for consideration of the subject Information Disclosure Statement. The petition fee (\$130.00) required by 37 CFR §1.17(i) is authorized in item 10 below; and				
		The required Statement is stated in item 9 below.				
	9.	Statement under 37 CFR 1.97(e)				
		Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or				
		b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.				
\boxtimes	10.	Please charge all applicable fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.				
		Respectfully submitted,				
		NIXON & VANDERHYE P.C.				
		By: Jeffry H. Nelson Reg. No. 30,481				
		# = O # = = = 1				

JHN:maw

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

INFO	RMATION DISCLOSURE CITATION	3659-1 APPLICA	10 OIPE	SERIAL NO. 09/618,759			
(Use several sheets if necessary)		LEVII	Net al L DEC 2 2 2000 1	GROUP			
·		July 18	8, 2000 R				
	·	U.	S. PATENT DOCUMENTS				
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING IF APPRO	DATE <u>OPRIATE</u>
		FOR	REIGN PATENT DOCUMENTS		<u> </u>	<u> </u>	
						TRANSI	ATION
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
							<u></u>
		•					
							-
							
	07//50 000			<u> </u>	<u> </u>		
			ncluding Author, Title, Date, Per				
5/1	8:No. 3, pp. 410-413 (w Volume Ultrafiltration Cell in Sma	all Children," C	linical Nepi	nrology	Vol.
	0.110. 3, pp. 410-413 (1977).					
					· · · · · · · · · · · · · · · · · · ·		
<u> </u>		<u> </u>		1 - 1	/ 48/3		
*Examiner	1 X es [-]		Date Considered	\bot \lesssim L	10/25		
			conformance with MPEP 609; Draw line through o	citation if not in confo	rmance and not	considered.	Include
copy or this for	n with next communication to applica	uon.			Form PTO-FR	A820 (Also	PTO-1449

RECEIVED

DEC 26 2000

TC 3700 MAIL ROOM